LOXL2 and cancer: This discovery further confirmed the involvement of fibroblasts in high-risk OV cancer, since TGFB1 is the driver of collagen accumulation produced by fibroblasts and immune suppression, and the inhibition of TGF-β signaling pathway and expression of LOXL2 depressed the fibroblast activities and pathological collagen accumulation [28].